Vitamin B3 Boosts Immune Attack on Glioblastoma in Early Clinical Trial
High-dose niacin revived suppressed immune cells in glioblastoma patients, with 82% showing no progression at 6 months — 28% better than expected.
Summary
Researchers at the University of Calgary are testing high-dose vitamin B3 (niacin) as an add-on treatment for glioblastoma, one of the deadliest brain cancers. Glioblastoma actively suppresses the immune system, allowing tumors to grow unchecked. Scientists found that niacin may 'reawaken' exhausted immune cells, restoring their ability to attack cancer. In a Phase I/II clinical trial involving 24 patients, 82% were progression-free at six months — a 28% improvement over historical benchmarks. The trial began with promising mouse studies showing extended survival, and human results have already surpassed the pre-set threshold needed to continue. While still early, these findings suggest a widely available, low-cost vitamin could meaningfully improve outcomes for a cancer with very few effective treatments.
Detailed Summary
Glioblastoma is one of the most aggressive and treatment-resistant brain cancers, with most patients surviving less than 15 months after diagnosis even with surgery, radiation, and chemotherapy. A team at the University of Calgary is now exploring whether high-dose vitamin B3 — niacin — can change those odds by restoring the immune system's ability to fight back.
The core problem is immune suppression. Glioblastoma tumors actively disable the immune cells that would normally attack them, creating a protected microenvironment that standard treatments struggle to overcome. Neuroscientist Dr. Wee Yong and oncologist Dr. Gloria Roldan Urgoiti hypothesized that niacin could reverse this suppression by rejuvenating exhausted immune cells, essentially rebooting the body's natural cancer-fighting machinery.
The researchers first validated the approach in mice, where niacin extended survival. They then launched a Phase I/II human clinical trial combining controlled-release niacin with standard chemotherapy and radiotherapy. Before enrolling patients, they set a clear benchmark: a 20% improvement in six-month progression-free survival over historical data. Results from the first 24 patients surpassed that target — 82% were progression-free at six months, representing a 28% improvement.
These results are scientifically meaningful because they cleared a pre-defined efficacy threshold, not just a statistical trend. The use of controlled-release niacin is also notable, as it helps manage the flushing side effect commonly associated with high-dose B3 supplementation.
Caveats are important here. This is an early-phase trial with a small sample size and no randomized control group, meaning results must be interpreted cautiously. Larger, randomized trials are needed to confirm efficacy and rule out confounding factors. Still, niacin's safety profile, low cost, and accessibility make it a compelling candidate worth watching closely in ongoing research.
Key Findings
- 82% of glioblastoma patients had no disease progression at 6 months, beating the historical benchmark by 28%.
- High-dose niacin appears to reactivate immune cells suppressed by glioblastoma tumors, restoring their cancer-killing function.
- The approach combines controlled-release vitamin B3 with standard chemotherapy and radiotherapy rather than replacing existing treatment.
- Animal studies showing extended survival preceded the human trial, providing a mechanistic basis for the clinical work.
- The trial pre-registered a minimum efficacy threshold, adding credibility to the positive early results.
Methodology
This is a science news report summarizing an active Phase I/II clinical trial conducted by University of Calgary researchers and published via ScienceDaily. The source institutions — Hotchkiss Brain Institute and Arnie Charbonneau Cancer Institute — are credible academic medical centers. Evidence basis is early-phase human trial data (n=24) supported by prior animal studies, with a pre-defined efficacy benchmark adding methodological rigor.
Study Limitations
The trial involves only 24 patients with no randomized control arm, making it impossible to fully rule out confounding variables or placebo effects. Long-term survival data and overall survival outcomes have not yet been reported. Readers should await peer-reviewed publication and larger Phase III trial results before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: